Get the Stockscreener App
1.00
2.19%
0.0214
Lucid Diagnostics Inc stock is traded at $1.00, with a volume of 724.56K.
It is up +2.19% in the last 24 hours and down -9.09% over the past month.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
See More
Previous Close:
$0.9786
Open:
$0.9869
24h Volume:
724.56K
Relative Volume:
0.61
Market Cap:
$108.19M
Revenue:
$4.35M
Net Income/Loss:
$-45.53M
P/E Ratio:
-0.9259
EPS:
-1.08
Net Cash Flow:
$-44.79M
1W Performance:
-9.91%
1M Performance:
-9.09%
6M Performance:
+4.40%
1Y Performance:
+25.00%
1-Day Range:
$0.9495
$1.01
1-Week Range:
$0.9495
$1.17
52-Week Range:
$0.7201
$1.80
Lucid Diagnostics Inc Stock (LUCD) Company Profile
Name
Lucid Diagnostics Inc
Sector
Industry
Phone
212 949 4319
Address
360 MADISON AVENUE, NEW YORK
Compare LUCD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LUCD
Lucid Diagnostics Inc
|
1.00 | 105.88M | 4.35M | -45.53M | -44.79M | -1.08 |
|
ABT
Abbott Laboratories
|
127.29 | 219.63B | 43.11B | 13.98B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
105.41 | 155.22B | 18.49B | 2.51B | 2.72B | 1.68 |
|
SYK
Stryker Corp
|
377.79 | 150.09B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
89.34 | 115.62B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
79.33 | 46.52B | 5.69B | 4.15B | 623.10M | 6.95 |
Lucid Diagnostics Inc Stock (LUCD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-27-21 | Initiated | Ascendiant Capital Markets | Buy |
| Nov-08-21 | Initiated | BTIG Research | Buy |
| Nov-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-08-21 | Initiated | Needham | Buy |
Lucid Diagnostics Inc Stock (LUCD) Latest News
Should I hold or sell Lucid Diagnostics Inc. stock in 2025Free Stock Signals For Fast Growth - jammulinksnews.com
PAVmed gets 180-day extension to regain Nasdaq listing compliance - MSN
PAVmed CEO and CFO to Present Q2 2025 Results and Growth Strategy Update on August 14 - Stock Titan
Cancer Prevention Leader Lucid Diagnostics to Reveal Q2 2025 Financial Results and Growth Strategy - Stock Titan
Lucid nearing Medicare coverage for EsoGuard test, maintain at Buy: BTIG - MSN
What explains LUCD's volatile earnings in 2024? - AInvest
Why did LUCD's Q4 earnings fall short of forecasts? - AInvest
What institutional investors are buying Lucid Diagnostics Inc. stockPre Market Forecasts Backed By Experts - jammulinksnews.com
How does Lucid Diagnostics Inc. compare to its industry peersStock Strategy Picks For 2025 - jammulinksnews.com
Lucid Diagnostics' Medicare Coverage Catalyst: A Strategic Inflection Point for Esophageal Cancer Prevention - AInvest
How many analysts rate Lucid Diagnostics Inc. as a “Buy”Achieve consistent profits with expert strategies - jammulinksnews.com
How does Lucid Diagnostics Inc. generate profit in a changing economyAchieve consistent profits with smart trading - jammulinksnews.com
When is Lucid Diagnostics Inc. stock expected to show significant growthGame-changing capital returns - jammulinksnews.com
What is Lucid Diagnostics Inc. company’s growth strategyAchieve consistent profits with proven methods - jammulinksnews.com
Is Lucid Diagnostics Inc. a growth stock or a value stockInvest confidently with professional market insights - jammulinksnews.com
What are the latest earnings results for Lucid Diagnostics Inc.Extraordinary market timing - jammulinksnews.com
Lucid Diagnostics Inc. Earnings Report Breakdown: What Investors Should KnowFree Stock Market Insider Analysis - Newser
What is the dividend policy of Lucid Diagnostics Inc. stockDiscover the next big stock winners - jammulinksnews.com
Sectors Driving Future Growth for Lucid Diagnostics Inc. StockDaily Price Surge List - Newser
Why Lucid Diagnostics Inc. stock attracts strong analyst attentionDaily Volume Leaders - metal.it
What drives Lucid Diagnostics Inc. stock priceHigh-yield growth strategies - PrintWeekIndia
What analysts say about Lucid Diagnostics Inc. stockFree Consultation - PrintWeekIndia
Is Lucid Diagnostics Inc. a good long term investmentStrong return on assets - jammulinksnews.com
Lucid Diagnostics Inc. Stock Analysis and ForecastBreakthrough capital growth - jammulinksnews.com
Immunovia's Strategic Hiring of Natalie Carfora: A Catalyst for Reimbursement Success and Market Expansion of PancreaSure - AInvest
Immunovia Names Natalie Carfora VP of Market Access and Reimbursement Ahead of PancreaSure Launch - AInvest
[New] Lucid Stock Price Prediction 2024, 2025 To 2050 - Exla Resources
Lucid says meeting scheduled to determine Medicare coverage for cancer test - MSN
LUCD’s 2025 Market Dance: Up 26.00% – Time to Invest? - investchronicle.com
what makes lucid diagnostics inc. stock price move sharply3x Growth Potential - Newser
Esophageal Cancer Detection Revolution: Lucid's Medicare Milestone and Its Market Impact - AInvest
Lucid says AdCom meeting set to determine cancer test coverage - Seeking Alpha
Lucid Diagnostics Inc. shares fall 5.98% intraday as MolDX convenes expert medical panel on Medicare. - AInvest
MolDX to Convene Expert Medical Panel on Medicare Local Coverage Determination (LCD) for Lucid Diagnostics' EsoGuard® Esophageal DNA Test - StreetInsider
How Lucid Diagnostics Inc. stock performs during market volatilityRisk Managed Trading Strategy - Newser
Lucid Diagnostics Inc Stock (LUCD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lucid Diagnostics Inc Stock (LUCD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Matheis Dennis | Director |
May 21 '25 |
Buy |
1.32 |
129,684 |
171,520 |
316,782 |
| Matheis Dennis | Director |
May 22 '25 |
Buy |
1.32 |
33,218 |
43,795 |
350,000 |
1.21%
0.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):